Interleukin 6: A Functional and Structural in Vitro Modulator of Beta-Cells from Islets of Langerhans

References

• Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen J H, Dinarello C A, Svenson M. Human PI 7 interleukin 1 is cytotoxic for pancreatic islets of Langerhans. Science 1986; 232: 1545–1547
   PubMed Web of Science ®Google Scholar
• Zawalich W S, Diaz V A. Interleukin 1 inhibits insulin secretion from isolated perifused rat islets. Diabetes 1986; 35(11)19–1123
   Google Scholar
• Sandler S, Anderson A, Hellerstrom C. Inhibitory effects of interleukin I on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinol 1987; 121: 1424–1431
   PubMed Web of Science ®Google Scholar
• Comens P G, Wolf B A, Unanue E R, Lacy P E, McDaniel M L. Interleukin I is potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 1987; 36: 963–970
   PubMed Web of Science ®Google Scholar
• del Rey A, Besedovsky H. Interleukin 1 affects glucose homeostasis. Am J Physiol 1987; 253: R794–R798
   PubMedGoogle Scholar
• Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergis-tic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes 1988; 37: 133–136
   PubMed Web of Science ®Google Scholar
• Cornell R P, Schwartz D B. Central administration of interleukin 1 elicits hyperinsulinemia in rats. Am J Physiol 1989; 256: R772–R777
   PubMedGoogle Scholar
• Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen J H, Dinarello C A. Ultrastructural studies of time-course and cellular specificity of interleukin-I mediated islet cytotoxicity. Acta Pathol Microbiol Immunol Scand Sect C 1987; 95: 55–63
   PubMedGoogle Scholar
• Sandler S, Bendtzen K, Borg L AH, Eizirik D L, Strandell E, Welsh N. Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin-ID indicate a perturbation in the mitochondrial function. Endocrinology 1989; 124: 1492–1501
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Bendtzen K, Dinarello C A, Nerup J. Human tumor necrosis factor potentiates human interleukin-I mediated rat pancreatic-cell cytotoxicity. J Immunol 1988; 139: 4077–4082
   Web of Science ®Google Scholar
• Campbell I L, Iscaro A, Harrison L C. IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to 1 murine islets of Langerhans. J Immunol 1988; 141: 2325–2329
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Rasmussen A K, Bech K, Feldt-Rasmussen U, Buschard K. Pathogenic role of inter-leukin 1 and tumor necrosis factor in autoimmune endocrine diseases. Clin Immunol Newslett 1988; 9: 72–74
   Google Scholar
• Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. Autoimmuniry 1989; 2: 177–189
   PubMed Web of Science ®Google Scholar
• Nerup J, Mandrup-Poulsen T, Mslvig J, Spinas G. Immune interactions with islet cells: Implications for the pathogenesis of insulin-dependent diabetes mellitus. The Pathology of the Endocrine Pancreas in Diabetes, P J Lefebvre, D G Pipeleers. Springer Verlag, Berlin 1989; 71–84
   Google Scholar
• Bendtzen K, Interleukin I. Interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 1988; 19: 183–192
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Ann Rev Immunol 1988; 6: 485–512
   PubMed Web of Science ®Google Scholar
• Brakenhoff J P, de Groot E R, Evers R F, Pannekoek H, Aarden L A. Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol 1987; 139: 4116–4121
   PubMed Web of Science ®Google Scholar
• Lansdorp P M, Aarden L A, Calafat J, Zeiljemaker W P. A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol 1986; 132: 105–113
   PubMed Web of Science ®Google Scholar
• van Darnme J, van Beeumen J, Decock B, van Snick J, de Ley M, Billiau A. Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-Iβ and hybridoma growth factor (HGF). Identification of leukocyte-derivated HGF as IL-6. J Immunol 1988; 140: 1534–1541
   PubMed Web of Science ®Google Scholar
• van Damme J, Cayphas S, van Snick J, Conings R, Put W, Lenaerts J P, Simpson R J, Billiau A. Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stirnulatory factor-2 (interleukin-6). Eur J Eiochem 1987; 168: 543–550
   PubMedGoogle Scholar
• Buschard K, Brogren C H, Röpke C, Rygaard J. Antigen expression of the pancreatic beta-cells is dependent on their functional state, as shown by a specific, BB-rat monoclonal autoantibody IC2. Acra Path Microbiol Immunol Scand 1988; 96: 342–346
   PubMed Web of Science ®Google Scholar
• Heding L G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diaberolo-gia 1972; 8: 260–266
   PubMed Web of Science ®Google Scholar
• Woloski BMRNJ, Smith E M, Meyer W J, Fuller G M, Blalock J E. Corticotropin-releasing activity of monokines. Science 1985; 230: 1035–1037
   PubMed Web of Science ®Google Scholar
• Castell J V, Gomez-Lechon M J, David M, Hirano T, Kishimoto T, Heinrich P C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human heptocytes. FEBS lett 1988; 232: 347–350
   PubMed Web of Science ®Google Scholar
• Ramadori G, van Damme J, Rieder H, Meyer zum Büchenfelde K H. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1β and tumor necrosis factor-α. Eur J Immunol 1988; 18: 1259–1264
   PubMed Web of Science ®Google Scholar
• Wyllie A H, Kerr J ER, Currie A R. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251–306
   PubMedGoogle Scholar
• Ghadially F N. Ultrastructural pathology of the cell. A Text and Atlas of Physiological and Pathological Alterations in Cell Fine Structure. Butterworths. London 1975; 448–451
   Google Scholar
• Eisenbarth G S. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360–1368
   PubMed Web of Science ®Google Scholar
• Foulis A K, Bottazzo G F. Insulitis in the human pancreas. The Pathology of the Endocrine Pancreas in Diabetes, P J Lefebvre, D G Pipeleers. Springer Verlag, Berlin 1989; 41–52
   Google Scholar
• Gepts W. Islet morphology in Type I diabetes. Behring Inst Mitt 1984; 75: 39–41
   Google Scholar
• Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura M, Terada E, Ikeda Y. Preventive effects of cyclosporin on diabetes in NOD mice. Diaberologia 1986; 29: 244–247
   PubMed Web of Science ®Google Scholar
• Feutren G, Assan R, Karsenty G, Du Rostu H, Sirmai J, Papoz L, Vialettes B, Vexiau P, Rodier M, Lallemand A. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2: 119–123
   PubMed Web of Science ®Google Scholar
• The Canadian-European Randomized Control Trial Group Cyclosporin-induced remission of IDDM after early intervention. Association of I yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574–1582
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Buschard K, Diamant M, Horn T, Svenson M, The Thyroid Cell Group. Possible role of IL-I, TNFa and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Lymphokine Res 1989; 8: 335–340
   PubMedGoogle Scholar